Metabolon, Inc.
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 5 name spellings.
18
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Method of Assessing Pancreatic Beta-cell Function (US 10,302,663) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Dec 20, 2026The maintenance fee for Compounds, Reagents, and Uses Thereof (US 11,680,042) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due May 17, 2027The maintenance fee for Apparatus and Associated Method for Analyzing Small Molecule Components in a Complex Mixture (US 9,189,595) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.
- 1 fee due Jun 10, 2027The maintenance fee for Diagnostic Methods, Therapeutic Agents and Uses Thereof (US 10,502,729) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 1 fee due Jul 21, 2027The maintenance fee for Biomarkers Related to Kidney Function and Methods Using the Same (US 10,539,575) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.
- 2 fees due Aug 2 to 25, 2027 · next Aug 2
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,949,475 | System and Method for Analyzing Metabolomic Data In force · High confidence | In force | High confidence | |
| US 7,807,138 | Biomarkers of Metabolic Responses to Hepatic Drugs In force · High confidence | In force | High confidence | |
| US 7,781,160 | Biomarkers Related to Metabolic Age and Methods Using the Same In force · High confidence | In force | High confidence | |
| US 7,561,975 | A System, Method, and Computer Program Product for Analyzing Spectrometry Data to Identify and Quantify Individual Components in a Sample In force · High confidence | In force | High confidence | |
| US 8,546,098 | Biomarkers for Monitoring Insulin Resistance and Methods Using the Same In force · High confidence | In force | High confidence | |
| US 8,809,008 | Biomarkers for Impaired Glucose Tolerance and Methods Using the Same In force · High confidence | In force | High confidence | |
| US 9,250,225 | Biomarkers for Insulin Resistance and Methods Using the Same In force · High confidence | In force | High confidence | |
| US 10,175,233 | Biomarkers for Cardiovascular Diseases and Methods Using the Same In force · High confidence | In force | High confidence | |
| US 8,187,830 | Method for Determining Insulin Sensitivity with Biomarkers In force · High confidence | In force | High confidence | |
| US 9,977,034 | Biomarkers for Fatty Liver Disease and Methods Using the Same In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 41: 4 patents in force now held by others · 13 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 16 abandoned · 5 no status recorded